DK1959955T3 - Fremgangsmåde til behandling af abnorm cellevækst - Google Patents
Fremgangsmåde til behandling af abnorm cellevækstInfo
- Publication number
- DK1959955T3 DK1959955T3 DK06820997.2T DK06820997T DK1959955T3 DK 1959955 T3 DK1959955 T3 DK 1959955T3 DK 06820997 T DK06820997 T DK 06820997T DK 1959955 T3 DK1959955 T3 DK 1959955T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell growth
- abnormal cell
- treating abnormal
- treating
- growth
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74276605P | 2005-12-05 | 2005-12-05 | |
| US86463706P | 2006-11-07 | 2006-11-07 | |
| PCT/IB2006/003397 WO2007066187A2 (en) | 2005-12-05 | 2006-11-23 | Method of treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1959955T3 true DK1959955T3 (da) | 2011-02-07 |
Family
ID=38123250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06820997.2T DK1959955T3 (da) | 2005-12-05 | 2006-11-23 | Fremgangsmåde til behandling af abnorm cellevækst |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7825137B2 (enExample) |
| EP (1) | EP1959955B1 (enExample) |
| JP (1) | JP4619346B2 (enExample) |
| KR (1) | KR101026676B1 (enExample) |
| AR (1) | AR056832A1 (enExample) |
| AT (1) | ATE488237T1 (enExample) |
| AU (1) | AU2006323027B2 (enExample) |
| BR (1) | BRPI0619424B1 (enExample) |
| CA (1) | CA2632286C (enExample) |
| CY (1) | CY1110931T1 (enExample) |
| DE (1) | DE602006018354D1 (enExample) |
| DK (1) | DK1959955T3 (enExample) |
| IL (1) | IL191471A (enExample) |
| NZ (1) | NZ568654A (enExample) |
| PL (1) | PL1959955T3 (enExample) |
| PT (1) | PT1959955E (enExample) |
| RU (1) | RU2384331C2 (enExample) |
| SI (1) | SI1959955T1 (enExample) |
| TW (1) | TWI321050B (enExample) |
| WO (1) | WO2007066187A2 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20104906B (en) | 2004-08-26 | 2010-02-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| PL1889836T3 (pl) * | 2005-08-24 | 2013-10-31 | Eisai R&D Man Co Ltd | Nowa pochodna pirydyny i pochodna pirymidyny (3) |
| KR101146852B1 (ko) * | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| EP2447359B1 (en) | 2006-04-14 | 2015-11-04 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| CN101454311B (zh) * | 2006-08-23 | 2013-03-27 | 卫材R&D管理有限公司 | 苯氧基吡啶衍生物的盐和其结晶及其制备方法 |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| JPWO2009104520A1 (ja) * | 2008-02-18 | 2011-06-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（２） |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
| WO2010064300A1 (ja) * | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| ES2667049T3 (es) | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Derivados de heteroaril-[1,8]naftiridina |
| JP2013519681A (ja) * | 2010-02-11 | 2013-05-30 | オーエスアイ・ファーマシューティカルズ，エルエルシー | ７−アミノフロピリジン誘導体 |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| AU2011276193B2 (en) | 2010-07-05 | 2015-01-22 | Merck Patent Gmbh | Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| AU2012223281A1 (en) * | 2011-03-03 | 2013-09-19 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| US9051318B2 (en) | 2011-03-09 | 2015-06-09 | Merck Patent Gmbh | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith |
| US20140350050A1 (en) * | 2011-09-21 | 2014-11-27 | Teligene Ltd. | Pyridine compounds as inhibitors of kinase |
| MY165215A (en) | 2012-01-31 | 2018-03-09 | Daiichi Sankyo Co Ltd | Pyridone derivatives |
| WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
| ES2655842T3 (es) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR y ROS1 en el cáncer |
| CN103509008A (zh) * | 2012-06-22 | 2014-01-15 | 康瑟特制药公司 | 吡唑取代的氨基-杂芳基化合物的衍生物 |
| WO2014020467A2 (en) | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Process for the preparation of pyrazole substituted aminoheteroaryl compounds |
| DK2898329T3 (en) | 2012-09-24 | 2017-07-17 | Ventana Med Syst Inc | PROCEDURE FOR IDENTIFYING TREATMENT RESPONSIBLE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC Lymphoma Kinase (ALK) AS MARKER |
| CA2890006C (en) * | 2012-11-06 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EA201201654A1 (ru) * | 2012-12-28 | 2014-06-30 | Ооо "Эн.Си.Фарм" | Противоопухолевое средство (варианты) |
| WO2014115169A2 (en) * | 2013-01-24 | 2014-07-31 | Hetero Research Foundation | Crizotinib solid dispersion |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| WO2014140159A1 (en) * | 2013-03-13 | 2014-09-18 | Ratiopharm Gmbh | Dosage form comprising crizotinib |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| JP6291179B2 (ja) * | 2013-07-26 | 2018-03-14 | 関東化學株式会社 | 光学活性２級アルコールの製造方法 |
| US20160214961A1 (en) * | 2013-09-10 | 2016-07-28 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| US12066428B2 (en) * | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| GB201616116D0 (en) * | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| CN108047231B (zh) * | 2018-01-02 | 2020-02-11 | 江苏医药职业学院 | [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用 |
| IT201800003875A1 (it) | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| EP4725489A2 (en) | 2019-08-02 | 2026-04-15 | OneHealthCompany, Inc. | Treatment of canine cancers |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| JPH07109260A (ja) | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法 |
| DE69536015D1 (de) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| SE9801526D0 (sv) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| NZ513639A (en) * | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6992087B2 (en) * | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| RS53118B (sr) * | 2003-02-26 | 2014-06-30 | Sugen Inc. | Aminoheteroaril jedinjenja kao inhibitori protein kinaze |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| BRPI0418801A (pt) * | 2004-05-05 | 2007-10-16 | Celgene Corp | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit |
| WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| GEP20104906B (en) * | 2004-08-26 | 2010-02-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| ATE492544T1 (de) * | 2004-08-26 | 2011-01-15 | Pfizer | Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer |
| KR101146852B1 (ko) * | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
-
2006
- 2006-11-23 BR BRPI0619424-9A patent/BRPI0619424B1/pt active IP Right Grant
- 2006-11-23 KR KR20087016376A patent/KR101026676B1/ko active Active
- 2006-11-23 DK DK06820997.2T patent/DK1959955T3/da active
- 2006-11-23 AT AT06820997T patent/ATE488237T1/de active
- 2006-11-23 EP EP06820997A patent/EP1959955B1/en active Active
- 2006-11-23 RU RU2008122471/14A patent/RU2384331C2/ru active
- 2006-11-23 CA CA2632286A patent/CA2632286C/en active Active
- 2006-11-23 AU AU2006323027A patent/AU2006323027B2/en active Active
- 2006-11-23 PL PL06820997T patent/PL1959955T3/pl unknown
- 2006-11-23 SI SI200630864T patent/SI1959955T1/sl unknown
- 2006-11-23 US US12/095,114 patent/US7825137B2/en active Active
- 2006-11-23 PT PT06820997T patent/PT1959955E/pt unknown
- 2006-11-23 DE DE602006018354T patent/DE602006018354D1/de active Active
- 2006-11-23 WO PCT/IB2006/003397 patent/WO2007066187A2/en not_active Ceased
- 2006-11-23 NZ NZ568654A patent/NZ568654A/en unknown
- 2006-12-04 JP JP2006327355A patent/JP4619346B2/ja active Active
- 2006-12-04 TW TW095145034A patent/TWI321050B/zh active
- 2006-12-05 AR ARP060105369A patent/AR056832A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191471A patent/IL191471A/en active IP Right Grant
-
2010
- 2010-11-24 CY CY20101101055T patent/CY1110931T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006323027A1 (en) | 2007-06-14 |
| WO2007066187A3 (en) | 2008-01-17 |
| CA2632286C (en) | 2011-11-15 |
| JP2007153894A (ja) | 2007-06-21 |
| EP1959955B1 (en) | 2010-11-17 |
| SI1959955T1 (sl) | 2011-02-28 |
| TW200727899A (en) | 2007-08-01 |
| DE602006018354D1 (de) | 2010-12-30 |
| KR101026676B1 (ko) | 2011-04-04 |
| BRPI0619424B1 (pt) | 2022-02-08 |
| CY1110931T1 (el) | 2015-06-10 |
| PT1959955E (pt) | 2011-01-04 |
| IL191471A (en) | 2013-03-24 |
| IL191471A0 (en) | 2009-08-03 |
| US7825137B2 (en) | 2010-11-02 |
| HK1126121A1 (en) | 2009-08-28 |
| JP4619346B2 (ja) | 2011-01-26 |
| ATE488237T1 (de) | 2010-12-15 |
| PL1959955T3 (pl) | 2011-04-29 |
| AR056832A1 (es) | 2007-10-24 |
| CA2632286A1 (en) | 2007-06-14 |
| US20080300273A1 (en) | 2008-12-04 |
| AU2006323027B2 (en) | 2012-08-02 |
| BRPI0619424A2 (pt) | 2011-10-04 |
| EP1959955A2 (en) | 2008-08-27 |
| WO2007066187A2 (en) | 2007-06-14 |
| RU2384331C2 (ru) | 2010-03-20 |
| RU2008122471A (ru) | 2009-12-10 |
| TWI321050B (en) | 2010-03-01 |
| KR20080072965A (ko) | 2008-08-07 |
| NZ568654A (en) | 2012-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL191471A0 (en) | Method of treating abnormal cell growth | |
| DK2343362T4 (da) | Forbedret fremgangsmåde til dyrkning af celler | |
| DK2072600T3 (da) | Fremgangsmåde til at forbedre jord | |
| DK2208469T3 (da) | Fremgangsmåde til fremstilling af en ortopædisk skæreblok | |
| DK3725329T3 (da) | Fremgangsmåde til hæmning af knogleresorption | |
| DK2135664T3 (da) | Fremgangsmåde til behandling af emissionsgas | |
| EP2184345A4 (en) | CELL SCREENING PROCESS | |
| DK1948852T3 (da) | Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden | |
| DK3428148T3 (da) | Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf | |
| DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
| DK1940250T3 (da) | Fremgangsmåde til stimulering af tarmfloraen | |
| PL2190883T3 (pl) | Sposób obróbki biomasy | |
| DK2212070T3 (da) | Fremgangsmåde til behandling af træ | |
| BRPI0716528A2 (pt) | mÉtodo de estabilizaÇço | |
| DK1907628T3 (da) | Kunstgræsstruktur og fremgangsmåde til fremstilling deraf | |
| DK2432798T3 (da) | 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme | |
| DK2342346T3 (da) | Thermotoga til behandling af biomasse | |
| EP1962892A4 (en) | INHIBITION OF CELL PROLIFERATION | |
| DK2080808T3 (da) | Fremgangsmåde til fremstilling af l-aminosyre | |
| EP2132570A4 (en) | SCREENING PROCESS | |
| EP2118273A4 (en) | METHOD FOR MODIFYING CELLS | |
| DK2079843T3 (da) | Fremgangsmåde til fremstilling af biogas | |
| DK1850662T3 (da) | Fremgangsmåde til forbedring af nematodetolerant eller- resistent plantevækst | |
| DK2441462T3 (da) | Fremgangsmåde til behandling af type I-diabetes | |
| DK2020845T3 (da) | Fremgangsmåde til høstning |